Anti-Xa activity after subcutaneous administration of dalteparin in intensive care unit patients with and without subcutaneous oedema

被引：0
|
作者：
M Rommers
N van der Lely
T Egberts
P van den Bemt
机构：
[1] TweeSteden Hospital and St Elisabeth Hospital Tilburg,Hospital Pharmacy Midden
[2] St Elisabeth Hospital,Brabant
[3] University of Utrecht,Intensive Care
[4] Institute of Pharmaceutical Sciences,Department of Pharmaco
来源：
Critical Care | / 9卷 / Suppl 1期
关键词：
Sequential Organ Failure Assessment; Sequential Organ Failure Assessment Score; Disseminate Intravascular Coagulation; Subcutaneous Administration; Dalteparin;
D O I：
10.1186/cc3403
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
    Rommers, Mirjam K.
    Van Der Lely, Netty
    Egberts, Toine C. G.
    Van den Bemt, Patricia M. L. A.
    [J]. CRITICAL CARE, 2006, 10 (03):
  • [2] Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study
    Mirjam K Rommers
    Netty Van Der Lely
    Toine CG Egberts
    Patricia MLA van den Bemt
    [J]. Critical Care, 10
  • [3] A SIMPLE TEST FOR MONITORING PLASMA ANTI-XA ACTIVITY IN PATIENTS AFTER SUBCUTANEOUS ADMINISTRATION OF ENOXAPARIN
    HALBMAYER, WM
    FEICHTINGER, C
    SCHWARZ, T
    GSCHNAIT, F
    STRASSER, A
    PRIESCHING, A
    FISCHER, M
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 1990, 102 (14) : 408 - 413
  • [4] Elevated Anti-Xa in the Setting of Prophylactic Unfractionated Subcutaneous Heparin Administration
    Weinstein, Tatiana
    Altshuler, Diana
    Lafond, Elyse
    Katz, Alyson
    [J]. JOURNAL OF PHARMACY PRACTICE, 2024, 37 (05) : 1209 - 1213
  • [5] Optimal, sparse sampling times of anti-factor Xa (anti-Xa) activity following subcutaneous enoxaparin administration in patients with chronic kidney disease (CKD).
    Overholser, BR
    Sowinski, KM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P40 - P40
  • [6] Anti-Xa levels after a subcutaneous injection of 5700 IU nadroparin in morbidly obese patients
    Diepstraten, J.
    Janssen, E. J. H.
    Hackeng, C. M.
    van Kralingen, S.
    van Dongen, E. P. A.
    Wiezer, M. J.
    van Ramshorst, B.
    Knibbe, C. A. J.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 315 - 315
  • [7] 4 HEPARIN PREPARATIONS - ANTI-XA POTENTIATING EFFECT OF HEPARIN AFTER SUBCUTANEOUS INJECTION
    JOHNSON, EA
    KIRKWOOD, TBL
    STIRLING, Y
    PEREZREQUEJO, JL
    INGRAM, GIC
    BANGHAM, DR
    BROZOVIC, M
    [J]. THROMBOSIS AND HAEMOSTASIS, 1976, 35 (03) : 586 - 591
  • [8] USE OF THE SUBCUTANEOUS ROUTE OF ADMINISTRATION OF MORPHINE IN THE INTENSIVE-CARE UNIT
    BRUERA, E
    GIBNEY, N
    STOLLERY, D
    MARCUSHAMER, S
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1991, 6 (04) : 263 - 265
  • [9] Evaluation of anti-Xa monitoring in children receiving enoxaparin in a cardiac intensive care unit
    Engdahl, Samantha
    Corcoran, Jason
    [J]. PHARMACOTHERAPY, 2014, 34 (06): : E112 - E112
  • [10] Monitoring of subcutaneous dalteparin in patients with renat insufficiency under intensive care: an observational study
    Kani, C
    Markantonis, SL
    Nicolaou, C
    Maggina, N
    [J]. JOURNAL OF CRITICAL CARE, 2006, 21 (01) : 79 - 84
12345